These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 19325498)
1. A phase I study of topotecan plus carboplatin for relapsed SCLC: WJTOG trial. Kurata T; Kashii T; Takeda K; Seki N; Tsuboi M; Kobayashi M; Satoh T; Nakagawa K; Fukuoka M J Thorac Oncol; 2009 May; 4(5):644-8. PubMed ID: 19325498 [TBL] [Abstract][Full Text] [Related]
2. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer. Gillenwater HH; McCune JS; Lindley C; Faucette S; Shord S; Donahue A; Socinski MA; Stewart CF; Zamboni WC; Kirstein MN; Moore D Cancer Invest; 2005; 23(6):511-9. PubMed ID: 16203659 [TBL] [Abstract][Full Text] [Related]
3. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial. Goto K; Ohe Y; Shibata T; Seto T; Takahashi T; Nakagawa K; Tanaka H; Takeda K; Nishio M; Mori K; Satouchi M; Hida T; Yoshimura N; Kozuki T; Imamura F; Kiura K; Okamoto H; Sawa T; Tamura T; Lancet Oncol; 2016 Aug; 17(8):1147-1157. PubMed ID: 27312053 [TBL] [Abstract][Full Text] [Related]
4. A phase I study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancer. Fukuda M; Nakamura Y; Kasai T; Nagashima S; Nakatomi K; Doi S; Nakano H; Takatani H; Fukuda M; Kinoshita A; Soda H; Tsukamoto K; Oka M; Kohno S; J Thorac Oncol; 2009 Jun; 4(6):741-5. PubMed ID: 19404211 [TBL] [Abstract][Full Text] [Related]
5. Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer. Heist RS; Fain J; Chinnasami B; Khan W; Molina JR; Sequist LV; Temel JS; Fidias P; Brainerd V; Leopold L; Lynch TJ J Thorac Oncol; 2010 Oct; 5(10):1637-43. PubMed ID: 20808253 [TBL] [Abstract][Full Text] [Related]
6. A phase I study of dose-dense topotecan given upfront to standard therapy in patients with small cell lung cancer. Garst J; Herndon JE; Shafman T; Campagna L; Blackwell S; Padilla K; Bjurstrom T; Andrews C; Maravich-May D; Anderson E; Crawford J Clin Drug Investig; 2006; 26(5):257-66. PubMed ID: 17163259 [TBL] [Abstract][Full Text] [Related]
7. Phase II trial of amrubicin and carboplatin in patients with sensitive or refractory relapsed small-cell lung cancer. Hirose T; Nakashima M; Shirai T; Kusumoto S; Sugiyama T; Yamaoka T; Okuda K; Ohnishi T; Ohmori T; Adachi M Lung Cancer; 2011 Sep; 73(3):345-50. PubMed ID: 21277039 [TBL] [Abstract][Full Text] [Related]
8. Phase II study of a 3-day schedule with topotecan and cisplatin in patients with previously untreated small cell lung cancer and extensive disease. Sorensen M; Lassen U; Jensen PB; Østerlind K; Jeppesen N; Jensen BB; Mellemgaard A; Rytter C; Langer SW J Thorac Oncol; 2008 Aug; 3(8):902-6. PubMed ID: 18670309 [TBL] [Abstract][Full Text] [Related]
9. A phase I study of weekly doxorubicin and oral topotecan for patients with relapsed or refractory small cell lung cancer (SCLC): A Fred and Pamela Buffet Cancer Center Clinical Trials Network study. Ernani V; Jahan R; Smith LM; Marr AS; Kimbrough SE; Kos ME; Tijerina J; Pivovar S; Lakshmanan I; Ketcham M; Rauth S; Mallya K; Nasser MW; Jain M; Kessinger A; Batra SK; Ganti AK Cancer Treat Res Commun; 2020; 22():100162. PubMed ID: 31675535 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of oral topotecan and bevacizumab combination as second-line treatment for relapsed small-cell lung cancer: an open-label multicenter single-arm phase II study. Spigel DR; Waterhouse DM; Lane S; Legenne P; Bhatt K Clin Lung Cancer; 2013 Jul; 14(4):356-63. PubMed ID: 23391616 [TBL] [Abstract][Full Text] [Related]
11. European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer. Ardizzoni A; Manegold C; Debruyne C; Gaafar R; Buchholz E; Smit EF; Lianes P; ten Velde G; Bosquee L; Legrand C; Neumaier C; King K; Clin Cancer Res; 2003 Jan; 9(1):143-50. PubMed ID: 12538462 [TBL] [Abstract][Full Text] [Related]
12. A phase I and pharmacological study of amrubicin and topotecan in patients of small-cell lung cancer with relapsed or extensive-disease small-cell lung cancer. Shibayama T; Hotta K; Takigawa N; Tada A; Ueoka H; Harita S; Kiura K; Tabata M; Segawa Y; Nogami N; Kuyama S; Shinkai T; Tanimoto M Lung Cancer; 2006 Aug; 53(2):189-95. PubMed ID: 16806573 [TBL] [Abstract][Full Text] [Related]
13. Phase II study of amrubicin combined with carboplatin for refractory relapsed small-cell lung cancer: North Japan Lung Cancer Group Trial 0802. Kawashima Y; Inoue A; Sugawara S; Oizumi S; Maemondo M; Okudera K; Suzuki T; Usui K; Harada M; Morikawa N; Hasegawa Y; Saito R; Ishimoto O; Sakakibara T; Asahina H; Nukiwa T Respir Investig; 2014 May; 52(3):190-4. PubMed ID: 24853020 [TBL] [Abstract][Full Text] [Related]
14. A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors. Seiden MV; Ng SW; Supko JG; Ryan DP; Clark JW; Lynch T; Huang KC; Kwiatkowski D; Skarin A; Eder JP Clin Cancer Res; 2002 Mar; 8(3):691-7. PubMed ID: 11895897 [TBL] [Abstract][Full Text] [Related]
15. Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial. Baize N; Monnet I; Greillier L; Geier M; Lena H; Janicot H; Vergnenegre A; Crequit J; Lamy R; Auliac JB; Letreut J; Le Caer H; Gervais R; Dansin E; Madroszyk A; Renault PA; Le Garff G; Falchero L; Berard H; Schott R; Saulnier P; Chouaid C; Lancet Oncol; 2020 Sep; 21(9):1224-1233. PubMed ID: 32888454 [TBL] [Abstract][Full Text] [Related]
16. A phase I clinical trial of weekly oral topotecan for relapsed small cell lung cancer. Agelaki S; Kontopodis E; Kotsakis A; Chandrinos V; Bompolaki I; Zafeiriou Z; Papadimitraki E; Stoltidis D; Kalbakis K; Georgoulias V Cancer Chemother Pharmacol; 2013 Jul; 72(1):45-51. PubMed ID: 23604531 [TBL] [Abstract][Full Text] [Related]
17. A phase II study of amrubicin and topotecan combination therapy in patients with relapsed or extensive-disease small-cell lung cancer: Okayama Lung Cancer Study Group Trial 0401. Nogami N; Hotta K; Kuyama S; Kiura K; Takigawa N; Chikamori K; Shibayama T; Kishino D; Hosokawa S; Tamaoki A; Harita S; Tabata M; Ueoka H; Shinkai T; Tanimoto M Lung Cancer; 2011 Oct; 74(1):80-4. PubMed ID: 21334093 [TBL] [Abstract][Full Text] [Related]
18. A phase I study of amrubicin combined with carboplatin for elderly patients with small-cell lung cancer. Inoue A; Yamazaki K; Maemondo M; Suzuki T; Kimura Y; Kanbe M; Isobe H; Nishimura M; Saijo Y; Nukiwa T J Thorac Oncol; 2006 Jul; 1(6):551-5. PubMed ID: 17409916 [TBL] [Abstract][Full Text] [Related]
19. A phase I/II trial of weekly topotecan and carboplatin in potentially platinum-sensitive relapsed ovarian and peritoneal carcinoma. Rose PG; Smrekar M; Haba P; Visser C; Beeler JF Gynecol Oncol; 2005 Dec; 99(3):714-9. PubMed ID: 16112177 [TBL] [Abstract][Full Text] [Related]
20. A phase I study of topotecan/paclitaxel alternating with etoposide/cisplatin and thoracic irradiation in patients with limited small cell lung cancer. Lu C; Komaki R; Lee JS; Shin DM; Palmer JL; Coldman BJ; Pisters KM; Kurie JM; Fossella FV; Glisson BS Clin Cancer Res; 2003 Jun; 9(6):2085-91. PubMed ID: 12796372 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]